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Recently, two protein-based vaccines have been approved for the prevention of invasive meningococcal disease caused byNeisse-
ria meningitidis serogroup B (MenB). It is therefore important to study carefully if and how these pathogens respond to wide-
spread vaccination. Traditionally, meningococci have been classified on the basis of capsular phenotypes, but variable levels of
capsule expression can influence the results, mainly amongMenB strains. In this issue, Jones and colleagues (J Clin Microbiol
54:25–34, 2016, http://dx.doi.org/10.1128/JCM.01447-15) compare whole-genome sequencing to traditional phenotypic methods
of classifying meningococci. They demonstrate that for MenB in particular, sequencing-based methods are far superior to tradi-
tional methods, especially when it comes to characterizing carriage isolates. This has important implications for future
surveillance.
The use of highly immunogenic protein-conjugated capsule-specific vaccines against Neisseria meningitidis serogroups A,
C, W, and Y has lowered the incidence of invasive meningococcal
disease (IMD) in several countries over the past 10 to 15 years.
Nevertheless, IMD remains a significant cause of morbidity and
mortality, especially in children and young adults worldwide.Me-
ningococci, including N. meningitidis serogroup B (MenB), are
commonly carried in the throats of asymptomatic young people
(1). It is believed that carriage strains are the main source of out-
breaks of IMD, although the mechanisms involved are poorly un-
derstood. The development of an effective vaccine against the
MenB capsule has been hampered by the low immunogenicity of
the B capsular polysaccharide. In addition, structural similarities
exist between the serogroup B polysaccharide capsule and neural
cell adhesion molecules, raising concerns about the potential
cross-reactivity to neural tissues of antibodies elicited by such a
vaccine (2). Development of a vaccine based on the serogroup B
capsule has thus been deemed unfeasible, although no indication
of increased neurologic effects has been observed following natu-
ral infections with MenB (3).
In 2000, a seminal study was published where whole-genome
sequencing (WGS) of a virulent MenB isolate was performed in
order to identify potential vaccine candidates (4). By using this
“reverse vaccinology” approach, the investigators identified pro-
teins that are expressed at the bacterial surface, are conserved
across a range of strains, and induce an effective antibody response
(4). The results provided the foundation for the subsequent devel-
opment of novel protein-based vaccines; two such vaccines have
recently been licensed.
The former of the two, Bexsero (Novartis Vaccines and Diag-
nostics) is a four-component vaccine directed against MenB
(4CMenB). It includes a combination of recombinant N. menin-
gitidis proteins, the NHBA fusion protein (derived from theNeis-
seria heparin-binding antigen), NadA (derived fromneisserial ad-
hesin A), the fHbp fusion protein (derived from factor H-binding
protein), and outer membrane vesicles containing the PorA P1.4
protein, produced by the fermentation of New Zealand MenB
strain NZ98/254 (5). Importantly, these proteins are not specific
to serogroup B and thus one intriguing question relates to their
ability to lower the rate of meningococcal carriage, irrespective of
serogroups. 4CMenB was licensed in the United States in January
2015 for use in persons 10 to 25 years old. Approval of the vaccine
was based on the demonstration of an immune response, as mea-
sured by serum bactericidal activity against three MenB strains
representative of the strains prevalent in the United States. How-
ever, the effectiveness of the vaccine against diverse serogroup B
strains has not been confirmed (5). Among college students in the
United Kingdom, the vaccine has been shown to reduce carriage
across serogroups (6).
Trumenba (Pfizer), or MenB-FHbp, another vaccine against
MenB that was licensed by the U.S. FDA in October 2014, is com-
posed of two recombinant lipidated factor H-binding protein
(fHbp) variants fromMenB, one from fHbp subfamily A and one
from subfamily B (A05 and B01, respectively) (7). According to
the FDA grading of recommendations assessment, development,
and evaluation, both vaccines received overall evidence type 2
(moderate level of evidence) for use in outbreak settings and type
3 (low level of evidence) for use in persons at increased risk of
serogroup Bmeningococcal disease (8). The Advisory Committee
on Immunization Practices in the United States has recom-
mended the use of MenB vaccines among persons 10 years old
who are at increased risk of IMD caused by this serogroup. This
includes those with complement deficiencies, anatomic or func-
tional asplenia, or routine exposure to meningococci in the labo-
ratory and those who are at an increased risk because of a disease
outbreak (category A recommendation). Additionally, vaccine se-
ries may be administered to adolescents and young adults 16 to 23
years old to provide short-term protection against most strains of
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MenB (category B recommendation). The preferred age range for
vaccination against MenB is 16 to 18 years (9).
In practice, the susceptibility of meningococci following vacci-
nationwith these novel protein-based vaccines will be determined
by the presence and level of antigen expression at the bacterial
surface, as well as the titer of complement-binding antibodies di-
rected against those antigens. It has been shown that the expres-
sion of the four meningococcal vaccine antigens used in 4CMenB
can change over time in the same individual (1). Therefore, the
long-term success of the new vaccines likely depends on their abil-
ity to suppress meningococcal colonization and the generation of
virulent escape mutants among the colonizing meningococcal
strains. Recent studies using a meningococcal antigen typing sys-
tem suggest that the recent coverage of 4CMenB against European
invasive isolates may be close to 78% (10).
In contrast to invasive strains, those found among asymptom-
atic carriersmay not express a capsule, despite having the requisite
capsular genes, because of phase variation. This makes the stan-
dard phenotypic (antibody-based) methods less sensitive for
strain characterization. This lack of sensitivity has potential impli-
cations for the surveillance of meningococcal carriage following
vaccination with the novelMenB vaccines. In this issue, Jones and
coworkers present the results of their comparative study of phe-
notypic and genotypic approaches toN. meningitidis capsule typ-
ing (11). The investigators looked at invasive (n 97) and carriage
(n  93) isolates from different populations, geographic loca-
tions, and time periods. Overall, the agreement between pheno-
typic and genotypicmethods was good for the invasive strains. On
the other hand, 35 (38%) of the carriage isolates had a complete
cps operon and 44 (47%) were capable of expressing a capsule
according to the sequence analysis and in theory should be sero-
groupable by phenotypic methods. However, phenotypic meth-
ods correctly identified the serogroups of only 17 to 19 (39 to 43%)
of the 44 strains. No genetic clues were provided as to the mech-
anism involved among organisms with an intact cps operon
that did not seem to express a capsule. Interestingly, the phe-
notypic methods performed poorly when it came to the MenB
isolates, correctly identifying only 4 to 6 of 17 serogroup B
carriage strains. Thus, antibody-based methods seem to be in-
herently insensitive for the characterization of these strains,
which could be the source of outbreaks. It would be of interest
to analyze the data from this study with respect to the presence
of the genes encoding NHBA, NadA, and fHbp. Similarly, the
data of Jones et al. (11) could also provide clues as to whyMenB
strains, in particular, seem to express their polysaccharide cap-
sule less avidly during carriage. This could be the result of a
combination of phase variation and deletions or insertions in
the cps locus. The WGS data generated by the investigators,
along with additional data from other collections of isolates,
could potentially give a more detailed picture of this phenom-
enon. Performing WGS is becoming more economically feasi-
ble as the cost continues to fall, gradually replacing reverse
transcription-PCR and multilocus sequence typing. Indeed,
the analysis and interpretation of sequence data are becoming
more significant rate-limiting steps in meningococcal genom-
ics than the cost of sequencing. As an added benefit of these
endeavors, further studies incorporating WGS coupled with
transcriptomics and proteomics may shed some light on the
pathogenic mechanisms involved in IMD, although the lack of
a good animal model still poses a constant challenge to basic
research in this field.
With the introduction and use of the two new MenB vaccines
on a large scale, monitoring studies will be of great importance in
assessing their effects on carriage, meningococcal population
structure, vaccine antigen variants, and herd immunity. Cur-
rently, studies in the United Kingdom indicate that 31 to 34% of
young university students carry meningococci in their throats, 9
to 10% carry MenB, and 7% carry serogroup Y (6). As of Septem-
ber 2015 in the United Kingdom, babies born on 1 July 2015 are
offered 4CMenB as part of the routine immunization schedule
and a catch-up campaign will be offered to babies born on 1 May
or later (12). The vaccinewill be given at 2, 4, and 12months of age
(13). Simultaneously, The Meningitis Research Foundation Me-
ningococcus Genome Library in the United Kingdom will per-
formWGSof invasive strains for epidemiological surveillance (12,
14). This is crucial for effective control and understanding of the
evolutionary trends resulting from vaccination (14). Information
onmeningococcal population structure and vaccine antigen vari-
ants will, it is hoped, become available in close-to-real time, facil-
itating genomic pathogen surveillance and improving our re-
sponses to this devastating infection.
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